United Kingdom

People: CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

16 Aug 2019
Change (% chg)

$0.27 (+2.98%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rowland, Lloyd 

Mr. Lloyd A. Rowland is Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. Mr. Rowland has served as our General Counsel since June 2018. Prior to joining our Company, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

Basic Compensation

Total Annual Compensation, USD 208,789
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,584,700
Fiscal Year Total, USD 1,793,490

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Sean McCarthy


Lloyd Rowland


Nick Galli


W. Michael Kavanaugh


Rachel Humphrey


Matthew Young

As Of  31 Dec 2018